| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79d23107654f7e83d937da0d1a1d3b00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a305f832ebc74c923043715dd06e42a0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D475-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D475-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2018-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c7d23cee2bd6c8fed6c78d126f5b336
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98a6ab61bb32fba00f0d8fd2873e79b3 |
| publicationDate |
2020-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3692042-A1 |
| titleOfInvention |
Treatment of obesity-related conditions |
| abstract |
The present invention relates to the discovery that the inhibition of element 2 of the solute transporter family (Slc6a2) exerts a sympathomimetic effect outside the brain that promotes weight loss without concomitant hypophagy or hyperkinesia. The invention provides compounds for inhibiting Slc6a2 outside the brain, as well as methods for promoting weight loss and treating obesity with such compounds. |
| priorityDate |
2017-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |